Janus Global Life Sciences Fund (JFNIX)

Sector Experts Seeking Growth and Innovation in Health Care



Inception Date12/31/1998
NAV (As of 4/27/17)$51.66
Total Net Assets (As of 3/31/17)$3.42B
Annual Expense Ratio
(As of fiscal year end 9/30/16)
GROSS 0.78%
NET 0.78%

Morningstar Fee Level
(As of 3/31/17)
Fee Level Group
(out of 390 funds)
Specialty Institutional

Performance (As of 3/31/17)
1 Year13.47%
3 Year10.23%
5 Year19.41%
10 Year12.90%
Morningstar (As of 3/31/17)
CategoryUS Fund Health
Overall Rating™
(Based on risk-adjusted returns)

View All Ratings

126 Funds Rated
Style Box

Returns quoted are past performance and do not guarantee future results; current performance may be lower or higher. Investment returns and principal value will vary; there may be a gain or loss when shares are sold. For the most recent month-end performance click here.

Returns greater than one year are annualized.

Straight Talk

Quarterly Commentary - Q1 2017


Global health care stocks rebounded during the quarter as investors worried less about political concerns and focused on the sector's strong fundamentals.

The Fund outperformed its benchmark, driven by biotechnology and health care equipment stocks.

We are excited about the potential for new product launches in 2017, which should help drive growth in the sector.


Andy Acker, CFA

Andy Acker, CFA

Fund Manager since 2007
Industry since 1996

Ethan Lovell

Ethan Lovell

Fund Manager since 2016
Industry since 1994